Last reviewed · How we verify
Pantoprazole high dose
Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells.
Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.
At a glance
| Generic name | Pantoprazole high dose |
|---|---|
| Also known as | zurcal, Controloc |
| Sponsor | Sherief Abd-Elsalam |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Pantoprazole binds to and inactivates the proton pump (H+/K+-ATPase) on the secretory surface of gastric parietal cells, preventing the final step of gastric acid production. This results in sustained reduction of both basal and stimulated gastric acid secretion. High-dose formulations are used to manage severe acid-related conditions and are particularly effective in treating gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger-Ellison syndrome.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Zollinger-Ellison syndrome
- Severe acid-related conditions requiring high-dose therapy
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Constipation
- Hypomagnesemia (with long-term use)
- Vitamin B12 deficiency (with long-term use)
Key clinical trials
- High Dose Oral Omeprazole in High Risk UGIB (NA)
- Non-opioid Anesthesia Based on Thoracic Paravertebral Block During Laparoscopic Sleeve Gastrectomy (NA)
- Anti-reflux Mucosal Valvuloplasty Versus PPIs for GERD Treatment (NA)
- 13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors) (PHASE4)
- The Selection Criteria for the Second-look Endoscopy Among Patients With Bleeding Peptic Ulcers
- Stereotactic Radiosurgery in Metastatic Spinal Cord Compression (NA)
- Efficacy of Low Dose Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding (NA)
- Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |